Thursday, July 3, 2025 7/3/2025

The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma

Award Number: R01CA216051
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2019
PERIOD OF PERFORMANCE END DATE: 11/30/2023

Group Awards By:

View Award Description

The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma - Project Summary Despite the dismal prognosis for patients with advanced lung squamous cell cancer (LUSC), few effective treatments of only limited benefit exist. Cytotoxic therapy with radiation remains the mainstay for most patients. However, it carries a relatively narrow therapeutic index and patients invariably suffer treatment-related systemic toxicities. The development of new targeted therapies for LUSC remains a high priority. One of the most significant discoveries from lung cancer genome sequencing is the frequent (~30%) alterations of the KEAP1- NRF2 signaling pathway. The NRF2 antioxidant signaling pathway constitutes the primary cellular defense system against oxidative stress. Several mechanisms responsible for governing NRF2 activity are known, however they have proven largely intractable for therapeutic intervention (eg. transcription factors). Recent studies have revealed that several protein kinases functionally impact NRF2, although a global evaluation of how the kinome instructs NRF2 biology remains untested. Being among the most druggable of protein classes, kinases and phosphatases offer attractive targets for NRF2-directed treatment intervention. Our preliminary data have established reciprocal communication between NRF2 and protein kinases, including upstream modifiers and downstream effectors. Therefore, we hypothesize that the kinome encompasses key regulators of NRF2 signaling and holds novel therapeutic targets for NRF2-active lung cancer. We have assembled a unique multidisciplinary team of investigators with experience in LUSC molecular signaling, cancer cell biology, animal and cell culture models, proteomics, and clinical therapeutics to decipher the interactions between the kinome and NRF2 signaling, identify novel therapeutic targets and analyze them in pre-clinical models. Our specific aims include: (1) IDENTIFY KINASES THAT REGULATE NRF2; (2) IDENTIFY NRF2-RESPONSIVE KINASES AND PHOSPHATASES; and (3) EVALUATE KINOME FUNCTION IN NOVEL MODELS OF NRF2 ACTIVE LUSC. This project shows strong innovation through kinome proteomic profiling of LUSC tumor samples and cell lines, high-throughput chemical screens, gain- and loss-of-function genetic screens, and the application of unique 2- and 3-dimensional cell culture models. Our experiments employ gene targeted-transformation of human bronchial epithelial cells and novel genetically engineered mouse models and derived cell lines. The results of this work will reveal protein kinases that functionally impact NRF2 biology, and in doing so may lead to new effective treatments for LUSC and other NRF2-active tumors, including head and neck cancer, bladder cancer, and ovarian cancer. Ultimately, the successful completion of our proposed studies will provide a roadmap for similar efforts on targeted therapeutic discovery in these other human malignancies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	WASHINGTON UNIVERSITY, THE	1 BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Cause and Prevention Research	000	5	4/10/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $493,661 )
2022	2022	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Cause and Prevention Research	001	5	5/19/2022	NON-COMPETING CONTINUATION	$40,299
2022	2022	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Cause and Prevention Research	000	5	11/11/2021	NON-COMPETING CONTINUATION	$453,362
														Subtotal = $493,661

Issue Date FY: 2021 ( Subtotal = $503,737 )
2021	2021	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Cause and Prevention Research	000	4	11/4/2020	NON-COMPETING CONTINUATION	$478,549
2021	2021	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Cause and Prevention Research	001	4	1/25/2021	NON-COMPETING CONTINUATION	$25,188
														Subtotal = $503,737

Issue Date FY: 2020 ( Subtotal = $517,517 )
2020	2020	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Cause and Prevention Research	003	3	6/18/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$10,388
2020	2020	WASHINGTON UNIVERSITY, THE	ONE BROOKINGS DR	SAINT LOUIS	MO	63130	SAINT LOUIS	USA	Cancer Cause and Prevention Research	001	3	3/2/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$517,517
2020	2019	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	002	2	6/18/2020	NON-COMPETING CONTINUATION	-$10,388
2020	2019	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	000	2	2/27/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $517,517

Issue Date FY: 2019 ( Subtotal = $485,161 )
2019	2019	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	000	2	11/16/2018	NON-COMPETING CONTINUATION	$485,161
														Subtotal = $485,161

Issue Date FY: 2018 ( Subtotal = $500,167 )
2018	2018	UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL	104 AIRPORT DR STE 2200	CHAPEL HILL	NC	27599	ORANGE	USA	Cancer Cause and Prevention Research	000	1	11/27/2017	NEW	$500,167
														Subtotal = $500,167

Grand Total All Awards = $2,500,243

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The Role of Protein Kinases in NRF2-driven Lung Squamous Cell Carcinoma

Award Number: R01CA216051

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2019

PERIOD OF PERFORMANCE END DATE: 11/30/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer